Compare Abeona Therapeutics Inc (ABEO) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Motorola Solutions Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Motorola Solutions Inc trades at $466.86 (market cap $76.45B). The key difference: Motorola Solutions Inc is far larger — about 180.2× Abeona Therapeutics Inc's market cap, and Motorola Solutions Inc pays a 1.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MSI | |
|---|---|---|
Market Cap | $424.33M | $76.45B |
Sector | Health | Technology |
52-Week High | $7.45 | $490.30 |
52-Week Low | $4.17 | $363.83 |
Enterprise Value | $279.23M | $85.36B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Motorola Solutions (MSI) trades at $467.55, down 1.38% on the day, yet maintains a strong bullish technical trend with moving averages signaling buy. The company reported robust Q2 2026 results, beating EPS estimates with $4.41 versus $3.85 expected, and raised full-year guidance amid record backlog of $15.6 billion. Revenue grew 13% year-over-year, driven by demand in public safety communications and software services. Valuation ratios remain elevated, with a P/E of 36.84 and P/S of 6.42, reflecting premium pricing for its growth trajectory.
Outlook is positive with analyst consensus price target of $533.80 implying 14% upside, supported by strong fundamentals and institutional accumulation. Key risks include execution challenges to meet raised guidance, high valuation sensitivity to earnings misses, and macroeconomic pressures on public sector spending. The stock's current level near pivot point resistance at $471 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
